Last reviewed 2026-04-20 · How we verify

Celiptium (ELLIPTINIUM)

Phase 2 active Small molecule Quality 28/100

Celiptium (generic name: ELLIPTINIUM) is a elliptinium drug. It is currently in Phase 2 development.

Celiptium works by blocking the Kit receptor, which helps control cell growth and division.

Celiptium (Elliptinium) is a small molecule drug targeting the mast/stem cell growth factor receptor Kit. It is classified as an elliptinium, but its commercial status and approved indications are unknown. The mechanism of action involves inhibiting the Kit receptor, which is involved in cell growth and proliferation. Further information on its safety, pharmacokinetics, and commercial status is not available.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ELLIPTINIUM
Drug class	elliptinium
Target	Fibroblast growth factor receptor 3, Mast/stem cell growth factor receptor Kit, Platelet-derived growth factor receptor alpha
Modality	Small molecule
Therapeutic area	Hematology
Phase	Phase 2

Mechanism of action

Think of it like a traffic light for cells. The Kit receptor is like a green light that tells cells to grow and multiply. Celiptium acts like a red light, stopping the green light from working and slowing down cell growth.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Celiptium CI brief — competitive landscape report
Celiptium updates RSS · CI watch RSS

Frequently asked questions about Celiptium

What is Celiptium?

Celiptium (ELLIPTINIUM) is a elliptinium drug.

How does Celiptium work?

Celiptium works by blocking the Kit receptor, which helps control cell growth and division.

What is the generic name of Celiptium?

ELLIPTINIUM is the generic (nonproprietary) name of Celiptium.

What drug class is Celiptium in?

Celiptium belongs to the elliptinium class. See all elliptinium drugs at /class/elliptinium.

What development phase is Celiptium in?

Celiptium is in Phase 2.

What does Celiptium target?

Celiptium targets Fibroblast growth factor receptor 3, Mast/stem cell growth factor receptor Kit, Platelet-derived growth factor receptor alpha and is a elliptinium.

Drug class: All elliptinium drugs
Target: All drugs targeting Fibroblast growth factor receptor 3, Mast/stem cell growth factor receptor Kit, Platelet-derived growth factor receptor alpha
Therapeutic area: All drugs in Hematology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing